Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease
T Masuda, D Nagata - Hypertension Research, 2023 - nature.com
Hypertension in chronic kidney disease (CKD) patients is a risk factor for end-stage renal
disease, cardiovascular events, and mortality. Thus, the prevention and appropriate …
disease, cardiovascular events, and mortality. Thus, the prevention and appropriate …
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
J Solomon, MC Festa, YS Chatzizisis… - Pharmacology & …, 2023 - Elsevier
Diabetes drives an increasing burden of cardiovascular and renal disease worldwide,
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
A Rastogi, JL Januzzi Jr - Journal of Clinical Medicine, 2023 - mdpi.com
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve
cardiovascular and renal outcomes in patients with established cardiovascular disease …
cardiovascular and renal outcomes in patients with established cardiovascular disease …
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
L Kugathasan, L Dubrofsky, A Advani… - Expert Review of …, 2023 - Taylor & Francis
Introduction Hypertension is a well-established risk factor for cardiovascular (CV) events in
patients with chronic kidney disease (CKD), heart failure, obesity, and diabetes. Despite the …
patients with chronic kidney disease (CKD), heart failure, obesity, and diabetes. Despite the …
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
A Vergara, C Jacobs-Cacha, MJ Soler - Clinical kidney journal, 2019 - academic.oup.com
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium–
glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce …
glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce …
Reno-and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
X Chen, CF Hocher, L Shen… - American Journal of …, 2023 - journals.physiology.org
Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
[HTML][HTML] Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics
NH Kim, NH Kim - Diabetes & Metabolism Journal, 2022 - synapse.koreamed.org
Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that
ultimately develops into end-stage kidney disease (ESKD) when not managed …
ultimately develops into end-stage kidney disease (ESKD) when not managed …
Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
F Oguz, N Demoulin, JP Thissen, M Jadoul… - Acta Clinica …, 2022 - Taylor & Francis
Chronic kidney disease (CKD) is a major public health problem, increasing the risk of
cardiovascular events and death and potentially leading to kidney failure. Novel drugs that …
cardiovascular events and death and potentially leading to kidney failure. Novel drugs that …
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
TW Kao, CC Huang - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-
directed medical therapy for heart failure with reduced ejection fraction. Recent trials clearly …
directed medical therapy for heart failure with reduced ejection fraction. Recent trials clearly …
相关搜索
- kidney disease sodium glucose
- cotransporter inhibitors sodium glucose
- fluid homeostasis sodium glucose
- kidney disease fluid homeostasis
- kidney disease inhibitors in patients
- cardiorenal axis sodium glucose
- blood pressure sodium glucose
- renoprotective mechanism sodium glucose
- renal hemodynamics sodium glucose
- pleiotropic effect sodium glucose
- kidney disease pleiotropic effects
- cardiorenal axis kidney physiology
- cotransporter inhibitors glycaemic control
- glycaemic control sodium glucose
- inhibitors in patients sodium glucose
- cardiovascular disease sodium glucose